Demant Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 3/6

Demant şirketinin toplam hissedar öz sermayesi DKK9.5B ve toplam borcu DKK13.1B olup, bu da borç-öz sermaye oranını 137.5% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla DKK32.4B ve DKK22.9B dir. Demant 'in FAVÖK'ü DKK4.0B faiz karşılama oranı 7.8 dur. Şirketin DKK1.0B tutarında nakit ve kısa vadeli yatırımları bulunmaktadır.

Anahtar bilgiler

137.5%

Borç/özkaynak oranı

DKK 13.10b

Borç

Faiz karşılama oranı	7.8x
Nakit	DKK 1.05b
Eşitlik	DKK 9.52b
Toplam yükümlülükler	DKK 22.87b
Toplam varlıklar	DKK 32.39b

Son finansal sağlık güncellemeleri

Güncelleme yok

Recent updates

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: DEMANC 'nin kısa vadeli varlıkları ( DKK10.7B ) kısa vadeli yükümlülüklerini ( DKK7.5B ) aşıyor.

Uzun Vadeli Yükümlülükler: DEMANC 'un kısa vadeli varlıkları ( DKK10.7B ) uzun vadeli yükümlülüklerini ( DKK15.4B ) karşılamamaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: DEMANC 'nin net borç/öz sermaye oranı ( 126.5% ) yüksek olarak değerlendiriliyor.

Borcun Azaltılması: DEMANC şirketinin borç/öz sermaye oranı son 5 yılda 95.3% seviyesinden 137.5% seviyesine yükseldi.

Borç Kapsamı: DEMANC 'nin borcu işletme nakit akışı ( 27.8% ) tarafından iyi bir şekilde karşılanmaktadır.

Faiz Kapsamı: DEMANC 'in borcuna ilişkin faiz ödemeleri EBIT ( 7.8 x kapsam) tarafından iyi bir şekilde karşılanmaktadır.

Demant Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 3/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Recent updates

Demant A/S Appoints Anne-Karen Hunt as President of Diagnostics Business Area, Effective 1 November 2024

Demant A/S Announces Board Changes

Demant A/S Updates Earnings Guidance for the Year 2024

Cochlear Limited (ASX:COH) acquired Oticon Medical A/s from Demant A/S (CPSE:DEMANT).

Cochlear Limited (ASX:COH) acquired Oticon Medical A/s from Demant A/S (CPSE:DEMANT).

Less than half of directors are independent

Demant A/S Provides Earnings Guidance for the Year 2024

Investor sentiment improves as stock rises 21%

Anja Madsen Announces Not to Stand for Re-Election to the Board of Directors of Demant A/S

Less than half of directors are independent

Demant A/S to Report Nine Months, 2024 Results on Nov 04, 2024

Less than half of directors are independent

Demant A/S Provides Earnings Guidance for the Year 2023

Less than half of directors are independent

Now 21% undervalued

Demant A/S Announces Executive Changes

Less than half of directors are independent

Investor sentiment improves as stock rises 16%

Less than half of directors are independent

Now 22% undervalued

Less than half of directors are independent

Less than half of directors are independent

Demant A/S to Report Fiscal Year 2022 Results on Feb 07, 2023

Less than half of directors are independent

Demant A/S Revised Earnings Guidance for the Full Year of 2022

Less than half of directors are independent

Investor sentiment deteriorated over the past week

Less than half of directors are independent

Demant A/S Revises Earnings Guidance for the Full Year 2022

Less than half of directors are independent

Less than half of directors are independent

Demant A/S (CPSE:DEMANT) acquired remaining 80% interest in ShengWang for CNY.

Less than half of directors are independent

Demant A/S Appoints Niels Wagner to the Board of Directors

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Less than half of directors are independent

Demant A/S Announces Update on Voluntary Field Corrective Action

Less than half of directors are independent

Demant A/Sreiterated Guidance for the Year 2021

Less than half of directors are independent

Less than half of directors are independent

Demant A/S Updates Earnings Guidance for the Year 2021

Independent Director has left the company

Independent Director has left the company

New 90-day high: kr.263

Full year 2020 earnings released: EPS kr.4.68 (vs kr.6.00 in FY 2019)

Revenue beats expectations

Demant A/S Announces Executive Changes

New 90-day high: kr.237

Demant Launches New Flagship Hearing aids

New 90-day high: kr.235

Demant A/S, Annual General Meeting, Mar 05, 2021

Demant A/S Revises Earnings Guidance for the Second Half of Fiscal Year 2020

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Sağlıklı şirketleri keşfedin